The one-time-only dose to stop SMA progression
ZOLGENSMA® (onasemnogene abeparvovec-xioi) is a gene therapy for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA)1
Getting started with ZOLGENSMA
Complete the ZOLGENSMA Prescription and Patient Consent Forms for eligible patients to help with insurance and prescription-related processes.
submit online download
Learn from SMA ExpertZ
Hear from leading neuromuscular specialists in our SMA ExpertZ series. Get tips on assisting families with treatment choice, accelerating early treatment, and navigating emerging challenges in SMA care.
Explore the series
Patient support
The OneGene Program®, offered by Novartis Gene Therapies, is a comprehensive, individualized support program for families with pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) and their healthcare providers throughout the ZOLGENSMA treatment journey.
OneGene Program support includes:
- Answers to questions about ZOLGENSMA
- A dedicated, personalized support team focused on the needs of each family
- Verification of insurance benefits
- Provide support on financial assistance programs for eligible patients
Families can access the full range of OneGene Program support resources when the ZOLGENSMA Prescription Form and accompanying Patient Consent Form have been provided to the OneGene Program.
For questions call 1-855-441-GENE (4363),
Monday-Friday (8 AM to 8 PM ET)
Discover more about ZOLGENSMA
About ZOLGENSMA
Explore efficacy, safety, dosing, and how ZOLGENSMA works
Understand SMA
Learn about the signs and symptoms of SMA
Steps to treatment
What to know before, during, and after infusion day
Resources
Learn about resources available to your patients
Reference: 1. ZOLGENSMA [prescribing information]. Bannockburn, IL: Novartis Gene Therapies, Inc; 2023.